| Variable (Mean ± SD) |
Subjects groups |
The mean difference |
P value |
| Experimental/Raloxifene (n=18) |
Control/placebo (n=19) |
| Age(y) |
60.9 ± 7.8 |
60.5 ± 7.5 |
0.4 |
0.891 |
| Duration of diabetes(y) |
7.8 ± 4.1 |
9.6 ± 4.5 |
1.8 |
0.244 |
| Duration of menopause(y)
|
11.3 ± 6.6 |
12.8 ± 9 |
1.5 |
0.595 |
| BMI
(kg/m2)
|
30.43 ± 4.15 |
29.29 ± 4.22 |
1.14 |
0.446 |
| SBP(mmHg) |
145 ± 15.6 |
143.4v19.9 |
1.6 |
0.806 |
| DBP(mmHg) |
87.2 ± 8.9 |
83.8 ± 10.9 |
3.4 |
0.337 |
| Variable |
Subjects groups |
Total number |
|
| Experimental/Raloxifene (n=18) |
Control/placebo (n=19) |
|
P value |
Ischemic heart disease(IHD)
Yes
No |
5(31.2%)
11(68.8%) |
5(31.2%)
11(68.8%) |
10(31.2%)
22(68.8%) |
1.000 |
Retinopathy
Yes
No |
7(43.8%)
9(56.2%) |
3(18.8%)
13(81.2%) |
10(31.2%)
22(68.8%) |
0.252 |
ACEI/ARB history
Yes
No |
13(81.2%)
3(18.8%) |
14(87.5%)
2(12.5%) |
27(84.4%)
5(15.6%) |
0.626 |
P value< 0.05 is considered statistically significant
BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure |
